FDA Clearance Tracker · P010032-S109
PROTEGE,PRODIGY,PROCLAIM ELITE FAMILY OF SCS IPGS AND SCS EPG
Last checked: Nov 20, 2026Latest source record: Oct 3, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Oct 3, 2016
Approved
Time to decision
297 days
Received Dec 11, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P010032-S109
- Device name
- PROTEGE,PRODIGY,PROCLAIM ELITE FAMILY OF SCS IPGS AND SCS EPG
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Plano, TX
- Received
- Dec 11, 2015
- Decided
- Oct 3, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P010032
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Clinician Programmer App (Version 3.2) Model 3874, Programmer App (Version 3.2) Model 3875, and the Protégé/Prodigy/Proclaim Elite family of SCS IPGs and SCS EPG which includes the following components:1) IPGs: Protégé (Models 3789), Prodigy (Model 3799), Protégé MRI (Model 377l), Prodigy MRI (Model 3772), and Proclaim 5 Elite (Model 3660); 2) Proclaim 7 Elite (Model 3662) SCS EPG Model 3599; 3) Patient Programmer Models 3855 and 3856; 4) Rapid Programmer Model 3834 (Version 3.7); 5) Clinician Programmer App Model 3874 (Version 3.2); and 6) Patient Controller App Model 3875 (Version 3.2).
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.